Rochester, NY 9/1/2009 9:21:12 AM
Acorda Therapeutics, Inc., ACOR, Down by 0.06 cents in Afternoon Trading
Acorda Therapeutics, Inc.
Acorda Therapeutics misses by $0.07, misses on revs Reports Q2 (Jun) loss of $0.62 per share, $0.07 worse than the First Call consensus of ($0.55); revenues rose 10.2% year/year to $12.6 mln vs the $13.3 mln consensus.
For the quarter ended June 30, 2009, the co reports combined gross sales of Zanaflex Capsules and Zanaflex tablets of $14.8 mln, compared to combined gross sales of $13.1 mln for the same quarter in 2008.
Whisperfromwallstreet.com is a FREE award winning newsletter dedicated to uncovering stocks that are about to move. Please click here to join now.
Last Trade: 22.62
Day's Range: 22.17 - 23.00
52wk Range: 14.42 - 33.00
Change: 0.06 (0.26%)
Volume: 405,860
Avg Vol (3m): 498,643
ABOUT Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc., a biopharmaceutical company, engages in the identification, development, and commercialization of various therapies for the improvement of neurological functions in people with multiple sclerosis (MS), spinal cord injury, and other disorders of the central nervous system in the United States. It markets Zanaflex Capsules and Zanaflex tablets, a short-acting drug indicated for the management of spasticity.
ABOUT WhisperFromWallStreet.com
WhisperFromWallStreet.com offers free daily stock alerts on companies ready to run. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
WhisperFromWallStreet.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified directly to their in-box.
This is a free service available only to our subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
During 2009 our alerts have resulted in an average price gain of 80%+.
Disclaimer: Full disclaimer at http://WhisperFromWallStreet.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
